Dr. Oleksandra Lupak
Claim this profileRalph H Johnson VA Medical Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
22 drugs studied
Area of expertise
1Lung Cancer
Stage IV
MET positive
EGFR positive
2Non-Small Cell Lung Cancer
Stage IV
MET positive
EGFR positive
Affiliated Hospitals
Clinical Trials Oleksandra Lupak is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Nivolumab + Standard Treatment
for Colorectal Cancer
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
Recruiting1 award Phase 2
More about Oleksandra Lupak
Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Oleksandra Lupak has experience with
- Lenalidomide
- Oxaliplatin
- Daratumumab/rHuPH20
- Screening Platform
- Daratumumab And Hyaluronidase-fihj
- Bortezomib
Breakdown of trials Oleksandra Lupak has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Oleksandra Lupak specialize in?
Oleksandra Lupak focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are MET positive.
Is Oleksandra Lupak currently recruiting for clinical trials?
Yes, Oleksandra Lupak is currently recruiting for 8 clinical trials in Charleston South Carolina. If you're interested in participating, you should apply.
Are there any treatments that Oleksandra Lupak has studied deeply?
Yes, Oleksandra Lupak has studied treatments such as Lenalidomide, Oxaliplatin, Daratumumab/rHuPH20.
What is the best way to schedule an appointment with Oleksandra Lupak?
Apply for one of the trials that Oleksandra Lupak is conducting.
What is the office address of Oleksandra Lupak?
The office of Oleksandra Lupak is located at: Ralph H Johnson VA Medical Center, Charleston, South Carolina 29401 United States. This is the address for their practice at the Ralph H Johnson VA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.